N-(5-ethoxycarbonylthiophen-2-yl)-2-pyrrolidinone | 1373621-68-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: N-(5-ethoxycarbonylthiophen-2-yl)-2-pyrrolidinone
• 英文别名: Ethyl 5-(2-oxo-1-pyrrolidinyl)-2-thiophenecarboxylate；ethyl 5-(2-oxopyrrolidin-1-yl)thiophene-2-carboxylate
• CAS: 1373621-68-1
• 化学式: C₁₁H₁₃NO₃S
• 分子量: 239.295
• InChiKey: VHCRUKGPUPMKOM-UHFFFAOYSA-N

物化性质

• 沸点：
  471.9±30.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(5-ethoxycarbonylthiophen-2-yl)-2-pyrrolidinone 在 水 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 5-(2-oxopyrrolidin-1-yl)thiophene-2-carboxylic acid
  参考文献：
  名称：

  [EN] SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF
  [FR] COMPOSÉS CONTENANT DES SPIROCYCLIQUES ET LEURS UTILISATIONS PHARMACEUTIQUES

  摘要：

  本发明涉及一种新型的共价激酶抑制剂家族，该类化合物已发现对TEC激酶家族的成员，特别是ITK和/或TXK，BTK，TEC和/或其组合具有抑制活性。本发明涉及一种具有I式结构的化合物或其药学上可接受的盐、溶剂、盐的溶剂体、立体异构体、互变异构体、同位素、前药、复合物或其生物活性代谢物，用于治疗。

  公开号：

  WO2018032104A1
• 作为产物：
  描述：

  2-吡咯烷酮 、 5-溴噻吩-2-甲酸乙酯 在 copper(l) iodide 、 potassium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-(5-ethoxycarbonylthiophen-2-yl)-2-pyrrolidinone
  参考文献：
  名称：

  [EN] SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF
  [FR] COMPOSÉS CONTENANT DES SPIROCYCLIQUES ET LEURS UTILISATIONS PHARMACEUTIQUES

  摘要：

  本发明涉及一种新型的共价激酶抑制剂家族，该类化合物已发现对TEC激酶家族的成员，特别是ITK和/或TXK，BTK，TEC和/或其组合具有抑制活性。本发明涉及一种具有I式结构的化合物或其药学上可接受的盐、溶剂、盐的溶剂体、立体异构体、互变异构体、同位素、前药、复合物或其生物活性代谢物，用于治疗。

  公开号：

  WO2018032104A1

文献信息

• Spirocyclic containing compounds and pharmaceutical uses thereof
  申请人：GB005, Inc.

  公开号：US10752615B2

  公开（公告）日：2020-08-25

  The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

  本发明涉及一种新型的共价激酶抑制剂家族，已发现该类化合物对TEC激酶家族成员，特别是ITK和/或TXK、BTK、TEC和/或其组合具有抑制活性。本发明涉及一种用于治疗的式I化合物或其药学上可接受的盐、溶解物、盐的溶解物、立体异构体、同分异构体、同位素、原药、复合物或生物活性代谢物。
• Copper-catalyzed oxidative C‒H, N‒H coupling of azoles and thiophenes
  作者：Shinobu Mitsuda、Taiki Fujiwara、Katsuyoshi Kimigafukuro、Daiki Monguchi、Atsunori Mori

  DOI：10.1016/j.tet.2012.03.001

  日期：2012.5

  C-H, N-H coupling of azole and thiophene derivatives takes place in the presence of a catalytic amount of Cu(OAc)(2) and an additive. The reaction of azoles smoothly occurs with several amines and amides catalyzed by 20 mol % of Cu(OAc)(2)-2PPh(3) and 4 equiv of NaOAc under O-2 or in the presence of Ag2CO3 under N-2. The coupling reaction leads to a facile synthesis of a N-substituted analogue of 2,5-diarylthiazole, which shows photoluminescent properties with extended pi-conjugation. Spectroscopic characteristics of the obtained thiazole derivatives are discussed by measurements of UV-vis absorption and photoluminescent spectra. Under the reaction conditions using Ag2CO3 as an additive and Cu(OAc)2-2PPh3 as a catalyst, thiophene derivatives also react with 2-pyrrolidone to undergo C-H, N-H amidation. (C) 2012 Elsevier Ltd. All rights reserved.
• SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF
  申请人：GB005, Inc.

  公开号：US20190263790A1

  公开（公告）日：2019-08-29

  The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.